Recombinant Human FGF-6 0 BewertungenSubmit a Review Produktdetails Katalognummer: 100-30 Beschreibung: FGF-6 is a secreted, heparin-binding growth factor that is a member of the FGF family. Proteins of this family play a central role during prenatal development, postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-6 is expressed in leukemia cell lines with platelet megakaryocytic differentiation potential. It signals through FGFR 1c, 2c, and 4. Recombinant Human FGF-6 is an 18.7 kDa protein consisting of 168 amino acid residues. Source: E.coli Synonyms: Fibroblast Growth Factor-6, HBGF-6, HST-2 AA Sequence: GTRANNTLLD SRGWGTLLSR SRAGLAGEIA GVNWESGYLV GIKRQRRLYC NVGIGFHLQV LPDGRISGTH EENPYSLLEI STVERGVVSL FGVRSALFVA MNSKGRLYAT PSFQEECKFR ETLLPNNYNA YESDLYQGTY IALSKYGRVK RGSKVSPIMT VTHFLPRI Purity: ≥ 95% by SDS-PAGE gel and HPLC analyses. Biological Activity: Determined by the dose-dependent stimulation of thymidine uptake by BaF3 cells expressing FGF receptors. The expected ED50 is ≤ 0.5 ng/ml corresponding to a specific activity of ≥ 2 x 106 units/mg. Calculated Molecular Weight: 18.7 kDa Accession Number: P10767 Gene ID: 2251 Endotoxin: Endotoxin level is < 0.1 ng/ug of protein (< 1 EU/ug) crossreactivity: Human, Mouse, References PubMed SDS Datenblattsuche Product Line Country Of Origin: USA Not for human use. Research Interest Angiogenesis/Cardiovascular Bone, Skeletal, Cartilage Cancer FGF Superfamily Immune System Inflammation Neurobiology Stem Cells & Differentiation Wound Healing product.subtitle.recentcitations Erstautor Savchenko, E Titel FGF family members differentially regulate maturation and proliferation of stem cell-derived astrocytes. Literaturstelle Scientific Reports; 9(1) pg9610 PubMed ID 31270389 Erstautor Ishihara, J Titel Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing. Literaturstelle Nature Communications; 9(1) pg2163 PubMed ID 29867149 Erstautor Shee, K Titel Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. Literaturstelle The Journal of Experimental Medicine; 215(3) pg895-910 PubMed ID 29436393
